GlassScriptPhysician profile
Christopher Ohalloran
NPI 1538123187
$17,522.39
in general payments reported to CMS, 2019-2025
45 companies · $2,704 in 2025
The $2,704 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,168 · 2020: $1,999 · 2021: $2,508 · 2022: $2,532 · 2023: $2,855 · 2024: $2,755 · 2025: $2,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,315.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,989.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,882.10 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,564.35 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,419.90 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $1,418.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,263.13 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $1,116.58 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,026.50 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $861.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $678.99 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $467.54 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Exact Sciences Corporation | $452.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $449.66 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $411.14 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $304.09 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ohalloran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.